Clinical trials: Advanced
Hepatocellular Carcinoma, Radioembolization
Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most-common cancer worldwide and the second most-common cause of cancer mortality. Liver resection is the first-line curative treatment for huge HCC.
- Trial name
- NCT02724436
- Testing
- TACE, radioembolization with Y-90
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Soft Tissue Sarcoma, Bone Sarcoma
Gemcitabine With Ascorbate Including Adolescents
The purpose of this research study is to see if a high dose of ascorbate (Vitamin C), in combination with the chemotherapy drug gemcitabine, is safe and effective in adolescents with locally advanced unresectable or metastatic…
- Conditions
- Soft Tissue Sarcoma, Bone Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Sarcoma
- Trial name
- NCT04877587
- Testing
- Ascorbate, Gemcitabine
- Where
- United States
- Sponsor
- David Dickens
Inflammatory Bowel Diseases (IBD), Crohn Disease
Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel Disease
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refractory, structurally complicated, postoperative, perianal, pouch-related, or psychosocially complex disease.
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn Disease, Colitis, Ulcerative
- Trial name
- DTT-IBD (NCT07877649)
- Testing
- Routine IBD Management and Advanced-Therapy Exposure
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Cancer
Expanded Access Program to Provide STC-15 to Patients With Selected Advanced Cancer
This Expanded Access Program (EAP) is intended to provide access to STC-15 outside of a clinical study setting for adult and adolescent patients with serious or life-threatening malignancies who, in the opinion of their treating…
- Trial name
- NCT07906093
- Testing
- STC-15
- Sponsor
- STORM Therapeutics LTD
Pediatric Neoplasm, Quality of Life
The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology
Over 50% of children dying from cancer still suffer from symptoms that could be effectively alleviated. The purpose of the Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST) Study was to evaluate whether…
- Conditions
- Pediatric Neoplasm, Quality of Life, Outcome Assessment, Palliative Care
- Trial name
- NCT01838564
- Testing
- Routine Data collection, Feedback of patient-reported outcomes
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Cancers
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
The goal of this clinical research study is to find the highest tolerable dose of the combination of Grifola frondosa extract, azacitidine, and lenalidomide that can be given to patients with advanced cancer.
- Trial name
- NCT01200004
- Testing
- Azacitidine, Lenalidomide, Grifola Frondosa
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Stomach Neoplasms
Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Middle or Upper Third Gastric Cancer
The purpose of this study is to explore the short-term, long-term and oncological outcomes of laparoscopic spleen-preserving No.
- Trial name
- LSPLN (NCT02333721)
- Testing
- D2 lymphadenectomy including No. 10, D2 lymphadenectomy excluding No. 10
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Fujian Medical University
Congenital Heart Disease, Advanced Heart Failure
TORCH-LATAM-003: Regional Advanced-Therapy Pathways for Congenital Heart Disease
TORCH-LATAM-003 is a pragmatic stepped-wedge cluster randomized trial evaluating a regional pathway for children and adults with congenital heart disease and advanced cardiac and/or respiratory failure who may require heart…
- Conditions
- Congenital Heart Disease, Advanced Heart Failure, Respiratory Failure, Heart Transplantation
- Trial name
- TORCH-003 (NCT07837024)
- Testing
- TORCH Congenital Advanced Therapies Pathway (TORCH-CATP)
- Volunteers
- 360 people
- Sponsor
- CardioVision International Tech, S.A.S. de C.V.
Liver Cancer
Tamoxifen in Treating Patients With Primary Liver Cancer
RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using tamoxifen may fight liver cancer by blocking the absorption of estrogen.
- Trial name
- NCT00003424
- Testing
- tamoxifen citrate
- Where
- 8 sites in Hong Kong, Indonesia and 4 more
- Volunteers
- 300 people
- Sponsor
- National Medical Research Council (NMRC), Singapore
Advanced Cancer
Bendamustine and Bevacizumab for Advanced Cancers
The goal of this clinical research study is to find the highest tolerable combination dose of bendamustine and bevacizumab that can be given to patients with advanced cancer.
- Trial name
- NCT01152203
- Testing
- Bendamustine, Bevacizumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients
A Randomized, Open label, Parallel-group, Multi-center study. Eligible patients will be randomized in a 1:1 ratio to receive fulvestrant 500 mg or Exemestane 25mg.
- Trial name
- FRIEND (NCT02646735)
- Testing
- Fulvestrant 500 mg, Exemestane 25 mg
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Chinese Academy of Medical Sciences
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma
Research Study in Patients With Advanced Ovarian Epithelial Cancer
This research trial studies tissue samples from patients with ovarian cancer in the laboratory. Analyzing tissue samples from patients in the laboratory may help doctors learn more about cancer.
- Conditions
- Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer
- Trial name
- NCT00053235
- Testing
- Comparative Genomic Hybridization, Laboratory Biomarker Analysis, Polymerase Chain Reaction
- Where
- United States
- Sponsor
- Gynecologic Oncology Group
Cancer, Patients Living With Stage IV or Recurrent Cancer
Quality of Care for Adolescent and Young Adult (AYA) Patients Living With Serious or Advanced Cancer
Background: Cancer among adolescents and young adults (AYAs) is on the rise, with nearly 90,000 AYAs diagnosed in the US each year.
- Trial name
- NCT07484282
- Testing
- Quality Assessment
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Insulin Pump Therapy
Closed Loop Pumps vs. Traditional Open Loop Pumps in Managing Blood Glucose Levels in T1DM Patients Fasting in Ramadan.
Our proposed study aims to build upon the existing findings by conducting a first-of-its-kind randomized controlled trial (RCT) that directly compares Advanced Hybrid Closed Loop (AHCL) and open-loop insulin delivery (OLID)…
- Trial name
- HybridRam (NCT06416202)
- Testing
- Advanced hybrid closed loop insulin pump, Open Loop Insulin Delivery system
- Where
- Saudi Arabia
- Volunteers
- 75 people
- Sponsor
- King Fahad Medical City
Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction
Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer
Identifying predictors of response to neoadjuvant therapy in gastric and gastro-oesophageal cancer early in the history of the disease would ensure optimal treatment planning.
- Trial name
- RADI-S (NCT06044961)
- Testing
- CT scan
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lung Cancer
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
This is an open-label, interventional, multiple-center, exploratory Phase II study sponsored by AstraZeneca Investment(China)Co., LTD.
- Trial name
- SOUND (NCT05374603)
- Testing
- Savolitinib, Durvalumab
- Where
- 16 sites in China
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
ALK Positive, ALK Positive Non-small Cell Lung Cancer
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)
- Conditions
- ALK Positive, ALK Positive Non-small Cell Lung Cancer, NSCLC, ALK+ Non-Small-Cell Lung Carcinoma
- Trial name
- NCT07784959
- Testing
- NXP900, Lorlatinib
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Nuvectis Pharma, Inc.
Neoplasms
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
- Trial name
- NCT06703346
- Testing
- Letetresgene autoleucel (Lete-Cel (GSK3377794)), Cyclophosphamide, Fludarabine
- Where
- 38 sites in United States, Canada and 5 more
- Volunteers
- 82 people
- Sponsor
- USWM CT, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.